fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Tamoxifen citrate

4 general benefit · 4 not a benefit

Apo-Tamox · DIN 00812404 · 10 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Apo-Tamox · DIN 00812404 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Marketed since 1989-12-31 · brand APO-TAMOX TAB 10MG · ATC L02BA01 TAMOXIFEN · form Tablet · route Oral · ingredients TAMOXIFEN (TAMOXIFEN CITRATE) 10 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Tamox: Formulary list price $0.18 per unit (the source does not state the unit; exact figure $0.1750). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00812404)

Source record
DIN 00812404: Apo-Tamox Raw flags: sec3=Y Item: 100000040; group id 185; item number 0334; lccId None; manufacturer id APX Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.1750; ministry $0.1750 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00812404 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10664
Interchangeable products
Nolvadex · DIN 02048477 · not recorded Tamofen · DIN 01926624 · not recorded Teva-Tamoxifen · DIN 00851965 · $0.1750
Shortage status: resolved shortage (ended July 24, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00812404
Shortage record checked October 6, 2026

Teva-Tamoxifen · DIN 00851965 · 10 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Teva-Tamoxifen · DIN 00851965 Manufacturer: Teva Canada Limited; listing date 1996-10-01 Health Canada: Marketed since 2011-06-01 · brand TEVA-TAMOXIFEN · ATC L02BA01 TAMOXIFEN · form Tablet · route Oral · ingredients TAMOXIFEN (TAMOXIFEN CITRATE) 10 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Tamoxifen: Formulary list price $0.18 per unit (the source does not state the unit; exact figure $0.1750). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00851965)

Source record
DIN 00851965: Teva-Tamoxifen Raw flags: sec3=Y Item: 100000040; group id 185; item number 0334; lccId None; manufacturer id TEV Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.1750; ministry $0.1750 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00851965 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10790
Interchangeable products
Apo-Tamox · DIN 00812404 · $0.1750 Nolvadex · DIN 02048477 · not recorded Tamofen · DIN 01926624 · not recorded
Shortage status: active shortage (reported April 3, 2024, last updated April 5, 2024) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00851965
Shortage record checked October 6, 2026

Apo-Tamox · DIN 00812390 · 20 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Apo-Tamox · DIN 00812390 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Marketed since 1989-12-31 · brand APO-TAMOX TAB 20MG · ATC L02BA01 TAMOXIFEN · form Tablet · route Oral · ingredients TAMOXIFEN (TAMOXIFEN CITRATE) 20 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Tamox: Formulary list price $0.35 per unit (the source does not state the unit; exact figure $0.3500). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00812390)

Source record
DIN 00812390: Apo-Tamox Raw flags: sec3=Y Item: 100000056; group id 185; item number 0335; lccId None; manufacturer id APX Source form: Tab; strength: 20mg Recorded listing: General benefit Source prices (unrounded): $0.3500; ministry $0.3500 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00812390 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10762
Interchangeable products
Nolvadex D · DIN 02048485 · not recorded Tamofen · DIN 01926632 · not recorded Teva-Tamoxifen · DIN 00851973 · $0.3500
Shortage status: resolved shortage (ended July 18, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00812390
Shortage record checked October 6, 2026

Teva-Tamoxifen · DIN 00851973 · 20 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Teva-Tamoxifen · DIN 00851973 Manufacturer: Teva Canada Limited; listing date 1996-10-01 Health Canada: Marketed since 2011-06-01 · brand TEVA-TAMOXIFEN · ATC L02BA01 TAMOXIFEN · form Tablet · route Oral · ingredients TAMOXIFEN (TAMOXIFEN CITRATE) 20 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Tamoxifen: Formulary list price $0.35 per unit (the source does not state the unit; exact figure $0.3500). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00851973)

Source record
DIN 00851973: Teva-Tamoxifen Raw flags: sec3=Y Item: 100000056; group id 185; item number 0335; lccId None; manufacturer id TEV Source form: Tab; strength: 20mg Recorded listing: General benefit Source prices (unrounded): $0.3500; ministry $0.3500 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00851973 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10791
Interchangeable products
Apo-Tamox · DIN 00812390 · $0.3500 Nolvadex D · DIN 02048485 · not recorded Tamofen · DIN 01926632 · not recorded
Shortage status: active shortage (reported February 7, 2024, last updated May 23, 2024) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00851973
Shortage record checked October 6, 2026

Nolvadex · DIN 02048477 · 10 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2003-04-01 — choose a marketed DIN from the same-category list.Discontinued April 1, 2003 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2003-04-01 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2003-04-01 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Nolvadex · DIN 02048477 Manufacturer: AstraZeneca; listing date 1996-10-01 Health Canada: Cancelled post market since 2003-04-01 · brand NOLVADEX TAB 10MG · ATC L02BA01 TAMOXIFEN · form Tablet · route Oral · ingredients TAMOXIFEN (TAMOXIFEN CITRATE) 10 MG · company Astrazeneca canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Nolvadex: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02048477)

Source record
DIN 02048477: Nolvadex Raw flags: notABenefit=Y, sec3=Y Item: 100000040; group id 185; item number 0334; lccId None; manufacturer id AZC Source form: Tab; strength: 10mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02048477 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16822
Interchangeable products
Apo-Tamox · DIN 00812404 · $0.1750 Tamofen · DIN 01926624 · not recorded Teva-Tamoxifen · DIN 00851965 · $0.1750
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02048477
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since April 1, 2003 — choose a marketed DIN from the same-category list.

Tamofen · DIN 01926624 · 10 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2011-01-11 — choose a marketed DIN from the same-category list.Discontinued January 11, 2011 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2011-01-11 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2011-01-11 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Tamofen · DIN 01926624 Manufacturer: Sanofi Aventis Pharma; listing date 1996-10-01 Health Canada: Cancelled post market since 2011-01-11 · brand TAMOFEN 10 · ATC L02BA01 TAMOXIFEN · form Tablet · route Oral · ingredients TAMOXIFEN (TAMOXIFEN CITRATE) 10 MG · company Sanofi-aventis canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Tamofen: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01926624)

Source record
DIN 01926624: Tamofen Raw flags: notABenefit=Y, sec3=Y Item: 100000040; group id 185; item number 0334; lccId None; manufacturer id SAV Source form: Tab; strength: 10mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01926624 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13043
Interchangeable products
Apo-Tamox · DIN 00812404 · $0.1750 Nolvadex · DIN 02048477 · not recorded Teva-Tamoxifen · DIN 00851965 · $0.1750
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01926624
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since January 11, 2011 — choose a marketed DIN from the same-category list.

Nolvadex D · DIN 02048485 · 20 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2023-03-22 — choose a marketed DIN from the same-category list.Discontinued March 22, 2023 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2023-03-22 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2023-03-22 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Nolvadex D · DIN 02048485 Manufacturer: AstraZeneca; listing date 1996-10-01 Health Canada: Cancelled post market since 2023-03-22 · brand NOLVADEX-D TAB 20MG · ATC L02BA01 TAMOXIFEN · form Tablet · route Oral · ingredients TAMOXIFEN (TAMOXIFEN CITRATE) 20 MG · company Astrazeneca canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Nolvadex D: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02048485)

Source record
DIN 02048485: Nolvadex D Raw flags: notABenefit=Y, sec3=Y Item: 100000056; group id 185; item number 0335; lccId None; manufacturer id AZC Source form: Tab; strength: 20mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02048485 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18639
Interchangeable products
Apo-Tamox · DIN 00812390 · $0.3500 Tamofen · DIN 01926632 · not recorded Teva-Tamoxifen · DIN 00851973 · $0.3500
Shortage status: discontinued (March 21, 2023, reported by ASTRAZENECA CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02048485
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since March 22, 2023 — choose a marketed DIN from the same-category list.

Tamofen · DIN 01926632 · 20 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2011-01-14 — choose a marketed DIN from the same-category list.Discontinued January 14, 2011 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2011-01-14 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2011-01-14 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Tamofen · DIN 01926632 Manufacturer: Sanofi Aventis Pharma; listing date 1996-10-01 Health Canada: Cancelled post market since 2011-01-14 · brand TAMOFEN 20 · ATC L02BA01 TAMOXIFEN · form Tablet · route Oral · ingredients TAMOXIFEN (TAMOXIFEN CITRATE) 20 MG · company Sanofi-aventis canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Tamofen: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01926632)

Source record
DIN 01926632: Tamofen Raw flags: notABenefit=Y, sec3=Y Item: 100000056; group id 185; item number 0335; lccId None; manufacturer id SAV Source form: Tab; strength: 20mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01926632 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13045
Interchangeable products
Apo-Tamox · DIN 00812390 · $0.3500 Nolvadex D · DIN 02048485 · not recorded Teva-Tamoxifen · DIN 00851973 · $0.3500
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01926632
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since January 14, 2011 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (L02B, L02BA): coverage varies; not interchangeable

  • Fulvestrant (Faslodex): general benefit
  • Abiraterone (Zytiga): general benefit
  • Anastrozole (Arimidex): general benefit
  • Bicalutamide (Casodex): general benefit, not a benefit
  • Degarelix (Firmagon): general benefit
  • Exemestane (Aromasin): general benefit

3 more in the class list below

Other drugs in the same formulary class (10:00 ANTINEOPLASTIC AGENTS) and how they are covered

Matched class: 10:00 ANTINEOPLASTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: ABIRATERONE ACETATE, ALTRETAMINE, ANASTROZOLE, BUSERELIN ACETATE, BUSULFAN, CAPECITABINE, CHLORAMBUCIL, CYPROTERONE ACETATE, DAUNORUBICIN, DEGARELIX ACETATE, ETOPOSIDE, EXEMESTANE, FLUOROURACIL & SALICYLIC ACID, FULVESTRANT, GOSERELIN ACETATE, HYDROXYUREA, IMATINIB MESYLATE, LETROZOLE, LEUPROLIDE ACETATE, MELPHALAN, MERCAPTOPURINE, MITOTANE, PROCARBAZINE HCL, TEMOZOLOMIDE, THIOGUANINE, TRIPTORELIN PAMOATE Some products covered without a code (check the product listing): BICALUTAMIDE, CYCLOPHOSPHAMIDE, FLUTAMIDE, LOMUSTINE (CCNU), MEGESTROL ACETATE, METHOTREXATE, VINCRISTINE SULFATE 10:00 ANTINEOPLASTIC AGENTS

FULVESTRANT

· 6 products · General benefit · strengths: 50mg/mL · Inj Sol

ABIRATERONE ACETATE

· 18 products · General benefit · strengths: 250mg, 500mg · Tab

ANASTROZOLE

· 18 products · General benefit · strengths: 1mg · Tab

BICALUTAMIDE

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 50mg · Tab

DEGARELIX ACETATE

· 2 products · General benefit · strengths: 80mg, 120mg · Pd for Inj-Vial Pk

EXEMESTANE

· 3 products · General benefit · strengths: 25mg · Tab

FLUTAMIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 250mg · Tab

LETROZOLE

· 20 products · General benefit · strengths: 2.5mg · Tab

ENZALUTAMIDE

· 5 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 40mg · Cap

ALTRETAMINE

· 1 products · General benefit · strengths: 50mg · Cap

BUSERELIN ACETATE

· 4 products · General benefit · strengths: 6.3mg, 9.45mg, 1mg/mL · Implant Kit, Inj Sol-5.5mL Pk, Nas Sp-10mL Pk

BUSULFAN

· 1 products · General benefit · strengths: 2mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 10:00 and 34 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS APO-TAMOX (tamoxifen tablets) is indicated for: • the adjuvant treatment of early breast cancer in women with estrogen receptor positive tumours. • the treatment of women with hormone responsive locally advanced/ metastatic breast cancer. 1.1 Pediatrics Pediatrics (< 18 years of age): the use of APO-TAMOX is not recommended in children, as safety and efficacy have not been established. https://pdf.hres.ca/dpd_pm/00081612.PDF PM date: OCT 17, 1989 Source product: APO-TAMOX TAB 20MG; DIN 00812390; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Teva-Tamoxifen · DIN 00851965 Shortage status: active shortage (reported 2024-04-03, last updated 2024-04-05) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00851965

Check this DIN again

Teva-Tamoxifen · DIN 00851973 Shortage status: active shortage (reported 2024-02-07, last updated 2024-05-23) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00851973

Check this DIN again

Nolvadex D · DIN 02048485 Shortage status: discontinued (2023-03-21, reported by ASTRAZENECA CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02048485

Check this DIN again
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Other review policies

For Nolvadex, Tamofen, Nolvadex D: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026